Curated News
By: NewsRamp Editorial Staff
September 03, 2024
Mainz Biomed Develops Breakthrough Colorectal Cancer Test
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Mainz Biomed's predictive test is poised to outperform existing solutions, providing a competitive advantage in colorectal cancer detection.
- Mainz's mRNA-powered test uses a portfolio of biomarkers to detect colon cancer risk with double the sensitivity of current products.
- Mainz's breakthrough device offers a new gold standard for noninvasive detection of advanced adenomas, potentially improving colorectal cancer survival rates.
- Mainz's next-generation FIT test, with AI and machine learning, represents a significant leap in noninvasive colorectal cancer detection technology.
Impact - Why it Matters
The development of a more effective and non-invasive colorectal cancer test by Mainz Biomed could significantly improve early detection and survival rates for this deadly disease. It also has the potential to impact the multi-billion dollar U.S. market for colorectal screening, as well as expand into other gastrointestinal cancers.
Summary
Actor Chadwick Boseman's death from colorectal cancer has brought attention to the threat posed by this disease. German company Mainz Biomed is developing a predictive test to address this threat, with a sensitivity for detecting precancerous polyps double that of current products on the market. The company has applied for FDA Breakthrough Device Designation for its non-invasive colorectal cancer product, which uses a portfolio of mRNA biomarkers, and has plans to conduct an FDA pre-market approval study in 2025.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Mainz Biomed Develops Breakthrough Colorectal Cancer Test
